|
Evotec AG is a drug discovery alliance and development partnership company focused on progressing product approaches with pharmaceutical and biotechnology companies. The company's headquarters are located in Hamburg, Germany. It operates worldwide providing integrated drug discovery solutions, covering all activities from target-to-clinic. Evotec employs over 500 scientists and works in key therapeutic areas including CNS/neurology (e.g. Alzheimer disease, Huntington's disease), metabolic diseases such as diabetes, as well as oncology, inflammation and infectious diseases. The company has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, the CHDI Foundation, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. In fiscal year 2013, Evotec generated revenues of €85.94 m. At the end of September 2014, Evotec had 718 employees. Since 28 October 2009 the company is listed in the TecDAX index. ==History== ''Evotec BioSystems GmbH'' was founded in Hamburg, Germany in 1993. Among the founders were Nobel Laureate Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Schulte, Rudolf Rigler and Charles Weissmann. In the first years the company established collaborations with international pharma companies like Novartis and SmithKlineBeecham to develop a high-throughput screening system (EVOscreen®). In 1999 ''Evotec Biosystems'' went public (Frankfurt Stock Exchange: EVT) and merged one year later with the British company ''Oxford Asymmetry International plc'', which offered chemical services for biotech and pharma companies and formed Evotec OAI (in 2005 the name changed to Evotec AG〔Evotec AG: Press Release: Evotec OAI Announces AGM Approval of Capital Increase and New Supervisory Board Structure, 7 June 2005, Retrieved 21 September 2011〕). In 2002 the company was divided into two business parts, namely “Discovery and Development Services“ and “Tools and Technologies“.〔Evotec OAI: Annual Report 2002〕 In this year ''Evotec Technologies GmbH'' was founded. In 2006 ''Evotec Technologies'' was sold to Perkin Elmer, to focus on its core business, the discovery and development of new pharmaceutical drugs. In 2008 Evotec acquired Renovis, an US biotech company and was listed on Nasdaq. One year later Evotec voluntarily delisted its ''American Depository'' Shares from the NASDAQ stock market to concentrate its share trading on the re-entered ''TecDAX'' platform and reduce associated costs.〔Evotec AG: Annual Report 2009〕 Additionally Evotec took over 70% of Indian ''Research Support International Limited'' (RSIPL), a company providing organic synthesis and a zebrafish screening-platform from Summit Corporation. In 2010 the company acquired ''DeveloGen AG'', a company focused on novel therapies for metabolic disorders, e.g. diabetes. In 2011 Evotec acquired two companies; ''Kinaxo Biotechnologies GmbH'', a Munich-based, privately owned biotech company. Kinaxo's capabilities comprise a combination of technologies improving drug development across the entire pharma value chain. Furthermore, Evotec took over the compound management business from ''Biofocus'', a subsidiary of the Galapagos group. In January 2013, Evotec acquired ''CCS Cell Culture Service GmbH'', a Hamburg-based company which supported the cell culture needs of biotech and pharmaceutical companies. In summer 2013, Evotec announced the closure of its Indian operations. In May 2014 Evotec acquired Euprotec for $3.15 million 〔http://www.genengnews.com/gen-news-highlights/evotec-buys-euprotec-for-up-to-3-15m/81249917/〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Evotec」の詳細全文を読む スポンサード リンク
|